Rats tested after a washout period from sub-chronic PCP administration exhibited impaired performance in the 5-Choice Continuous Performance Test (5C-CPT) when the attentional load was increased
Open accessThe DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Abstract
It is well documented that schizophrenia patients exhibit dysfunction in various cognitive domains, including attention/vigilance, as demonstrated by impaired performance in the myriad of continuous performance tests (CPTs). NMDA receptor antagonists provide a pharmacological model in animals of the cognitive disruption presented in the disorder. We therefore examined the effects of a sub-chronic PCP treatment regimen (5.0 mg/kg 7-days bi-daily) in the recently developed rodent test of vigilance, the 5 Choice-Continuous Performance Test (5C-CPT). We assessed the effects of this regimen after at least a 7-day washout period on both baseline performance and when the attentional load was increased. Sub-chronic PCP-treatment impaired 5C-CPT performance in a manner consistent with impaired vigilance in patients with schizophrenia, with reduced hit rate and impaired signal sensitivity. These effects were only evident when performance was challenged following parameter manipulations. These data demonstrate that attention/vigilance is sensitive to disruption following sub-chronic PCP treatment in a pre-clinical task that may demonstrate increased analogy to human vigilance tasks. Although the PCP-induced attentional deficits are not as large as those deficits observed in other domains, these data provide evidence that this pharmacological model can affect multiple cognitive domains and may be useful for assessing putative pro-cognitive therapeutics for schizophrenia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Recent advances in the phencyclidine model of schizophrenia
(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.10.1301 · Cited by 2,904
The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity
Nuechterlein, K. H., Green, M. F., Kern, R. S., Baade, L. E., Barch, D. M., Cohen, J. D., Essock, S., Fenton, W. S., Frese, F. J., Gold, J. M., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07010042 · Cited by 2,342
NMDA receptor hypofunction model of schizophrenia
Olney, J. W., Newcomer, J. W., & Farber, N. B. (1999) · Journal of Psychiatric Research · doi:10.1016/s0022-3956(99)00029-1 · Cited by 1,020
Glutamate and Schizophrenia: Beyond the Dopamine Hypothesis
Coyle, J. T. (2006) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9062-8 · Cited by 917 · cited 1×
“…NMDA receptor(s) and/or abnormal downstream NMDA receptor effects being core to the pathophysiology of the disease (Olney and Faber, 1995; Olney et al. 1999; Goff and Coyle, 2001), potentially providing a more compelling model than the hyperdopaminergic hypothesis of schizophrenia (Coyle, 2006).”
BackgroundThe MATRICS Consensus Cognitive Battery, part 2: co-norming and standardization
Kern, R. S., Nuechterlein, K. H., Green, M. F., Baade, L. E., Fenton, W. S., Gold, J. M., Keefe, R. S. E., Mesholam-Gately, R., Mintz, J., Seidman, L. J., et al. (2008) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2007.07010043 · Cited by 744
Eagle, D. M., Bari, A., & Robbins, T. W. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1127-6 · Cited by 548 · cited 4×
“CPTs) may be the result of inattentiveness, stimulus discrimination inability, or poor impulse control (Eagle et al. 2008) and are important to consider, when assessing vigilance (Mackworth et al.”
BackgroundInfluentialGranon, S., Passetti, F., Thomas, K. L., Dalley, J. W., Everitt, B. J., & Robbins, T. W. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-03-01208.2000 · Cited by 546
Chudasama, Y., Passetti, F., Rhodes, S. E. V., Lopian, D., Desai, A., & Robbins, T. W. (2003) · Behavioural Brain Research · doi:10.1016/j.bbr.2003.09.020 · Cited by 518 · cited 2×
“…(Carli et al. 1983; Mirza and Stolerman, 1998; Stolerman et al. 2000; Grottick and Higgins 2002; Hahn et al. 2002; Hahn et al. 2003; Winstanley et al. 2003; Chudasama et al. 2003; Young et al. 2007), manipulations that include reducing the stimulus duration or extending the session length.”
BackgroundMethodAcetylcholine contributes through muscarinic receptors to attentional modulation in V1
Herrero, J. L., Roberts, M. J., Delicato, L. S., Gieselmann, M. A., Dayan, P., & Thiele, A. (2008) · Nature · doi:10.1038/nature07141 · Cited by 459
Buchanan, R. W. (2005) · Schizophrenia Bulletin · doi:10.1093/schbul/sbi020 · Cited by 438
Morgan, C. J. A., Muetzelfeldt, L., & Curran, H. V. (2010) · Addiction · doi:10.1111/j.1360-0443.2009.02761.x · Cited by 373
Dalley, J. W., McGaughy, J., O'Connell, M. T., Cardinal, R. N., Levita, L., & Robbins, T. W. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-13-04908.2001 · Cited by 277 · cited 3×
“Noradrenergic depletion also impairs rats’ ability to adapt to variable ITI challenges (when trained with a constant ITI) in the 5-CSRTT (Cole and Robbins, 1992), while noradrenaline levels as measured by microdialysis only increase during such challenges (Dalley et al. 2001).”
BackgroundGrottick, A. J., & Higgins, G. A. (2000) · Behavioural Brain Research · doi:10.1016/s0166-4328(00)00305-3 · Cited by 240 · cited 1×
“Interestingly, acute administration of MK-801 has been shown to reduce CL in the 5-CSRTT (Grottick and Higgins, 2000), an effect that was absent at a higher dose.”
BackgroundWinstanley, C. A., Chudasama, Y., Dalley, J. W., Theobald, D. E. H., Glennon, J. C., & Robbins, T. W. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1398-x · Cited by 234
Impaired attention is central to the cognitive deficits observed in alpha 7 deficient mice
Young, J. W., Crawford, N., Kelly, J. S., Kerr, L. E., Marston, H. M., Spratt, C., Finlayson, K., & Sharkey, J. (2007) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2006.03.008 · Cited by 233 · cited 4×
“…(Carli et al. 1983; Mirza and Stolerman, 1998; Stolerman et al. 2000; Grottick and Higgins 2002; Hahn et al. 2002; Hahn et al. 2003; Winstanley et al. 2003; Chudasama et al. 2003; Young et al. 2007), manipulations that include reducing the stimulus duration or extending the session length.”
BackgroundMethodInfluentialSelf-citationAbdul-Monim, Z., Neill, J. C., & Reynolds, G. P. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881107067097 · Cited by 206 · cited 4×
“…uthor M anuscript A uthor M anuscript metabolic disturbances in the drug free state, mirroring alterations evident in pathology of the disorder (Jentsch et al. 1997a; Jentsch et al. 1997b; Cochran et al. 2003; Hajszan et al. 2006; Abdul-Monim et al. 2007; Jenkins et al. 2008; Snigdha et al. 2010).”
BackgroundInfluentialSelf-citationDalley, J. W. (2004) · Cerebral Cortex · doi:10.1093/cercor/bhh052 · Cited by 191
Hahn, B., Shoaib, M., & Stolerman, I. (2002) · Psychopharmacology · doi:10.1007/s00213-002-1005-6 · Cited by 188
Vigilance, arousal and habituation
Mackworth, J. F. (1968) · Psychological Review · doi:10.1037/h0025896 · Cited by 157 · cited 1×
“Responses during non-target trials in go/nogo tasks (e.g. CPTs) may be the result of inattentiveness, stimulus discrimination inability, or poor impulse control (Eagle et al. 2008) and are important to consider, when assessing vigilance (Mackworth et al. 1952; Mackworth, 1968).”
BackgroundMurphy, E. R., Dalley, J. W., & Robbins, T. W. (2005) · Psychopharmacology · doi:10.1007/s00213-004-2068-3 · Cited by 145
Attentional effects of nicotinic agonists in rats
Hahn, B., Sharples, C. G. V., Wonnacott, S., Shoaib, M., & Stolerman, I. P. (2003) · Neuropharmacology · doi:10.1016/s0028-3908(03)00099-6 · Cited by 135 · cited 1×
“…taxing attentional processing (Carli et al. 1983; Mirza and Stolerman, 1998; Stolerman et al. 2000; Grottick and Higgins 2002; Hahn et al. 2002; Hahn et al. 2003; Winstanley et al. 2003; Chudasama et al. 2003; Young et al. 2007), manipulations that include reducing the stimulus duration or…”
BackgroundPhencyclidine exacerbates attentional deficits in a neurodevelopmental rat model of schizophrenia
Le Pen, G., Grottick, A. J., Higgins, G. A., & Moreau, J.-L. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300208 · Cited by 82
Differentiating between ADHD sub‐types on CCPT measures of sustained attention and vigilance
EGELAND, J., JOHANSEN, S. N., & UELAND, T. (2009) · Scandinavian Journal of Psychology · doi:10.1111/j.1467-9450.2009.00717.x · Cited by 74 · cited 2×
“Vigilance in humans reflects the ability to remain alert towards incoming stimulus information (Collings, 2003; Egeland et al. 2009) and is *Correspondence: Prof Jo Neill, School of Pharmacy, University of Bradford, Richmond Road, Bradford, BD7 1DP, Tel: +44 1274 234677, Fax: +44 1274 234660,…”
Background
Cited by
Mice with reduced DAT levels recreate seasonal-induced switching between states in bipolar disorder
Young, J. W., Cope, Z. A., Romoli, B., Schrurs, E., Joosen, A., van Enkhuizen, J., Sharp, R. F., & Dulcis, D. (2018) · Neuropsychopharmacology · doi:10.1038/s41386-018-0031-y · Cited by 81
Self-citationYoung, J. W., Meves, J. M., & Geyer, M. A. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.11.028 · Cited by 69
Self-citationCope, Z. A., Minassian, A., Kreitner, D., MacQueen, D. A., Milienne-Petiot, M., Geyer, M. A., Perry, W., & Young, J. W. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2017.07.031 · Cited by 27
“Although the precise mechanism underlying this effect remains to be determined, the availability of rat and mouse 5C-CPTs (Barnes et al., 2012a, b; Young et al., 2015; Young et al., 2011b) enables the use of neuroscience techniques to determine underlying mechanisms.”
Self-citation
Metadata
- Authors
- Barnes, S. A., Young, J. W., & Neill, J. C.
- Venue
- Neuropharmacology
- Publisher
- Elsevier BV
- Published
- 2012-03
- Volume
- 62
- Issue
- 3
- Pages
- 1432-1441
- ISSN
- 0028-3908 (ISSN-L)
- OpenAlex
- W1998128151
- Cited by
- 61
- References
- 23
- FWCI
- 3.94
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.